Cardiovascular medications
Pro Research Analysisby 
Searched over 200M research papers for "cardiovascular medications"
Cardiovascular Medications: Prevalence, Benefits, and Risks
Cardiovascular medications are widely used to manage conditions such as hypertension, heart failure, and coronary artery disease. These drugs are essential for reducing morbidity and mortality associated with cardiovascular diseases, which are among the leading causes of death globally Chrysant2020Wirtz2016.
Medication Harm and Safety Concerns with Cardiovascular Drugs
Cardiovascular medications are a leading cause of medication-related harm, especially in older adults. They account for about 20% of all medication harm, and this figure rises to 50% in older populations. The most common types of harm include kidney injury, electrolyte imbalances, and low blood pressure. Medications for high blood pressure and abnormal heart rhythms are particularly implicated. Many of these harms are preventable, highlighting the need for careful prescribing and regular review, especially in elderly patients .
Despite their high risk, cardiovascular medications are often under-recognized in clinical guidelines compared to other high-risk drugs. Experts recommend including cardiovascular medications in all high-risk medication guidelines to improve patient safety .
Cardiovascular Drug Toxicity and Adverse Effects
A wide range of pharmaceuticals, including cardiovascular drugs, can cause cardiovascular toxicity. This includes drugs that prolong the QT interval, antidysrhythmic drugs, digoxin, beta-blockers, calcium channel blockers, and certain anticancer agents. Illicit drugs like cocaine and amphetamines also contribute to cardiovascular toxicity. Understanding the mechanisms of toxicity and appropriate treatment is crucial for healthcare providers .
Neuropsychiatric Effects of Cardiovascular Medications
Some cardiovascular medications can cause neuropsychiatric side effects such as fatigue, sedation, mood changes, psychosis, and cognitive disturbances. While earlier studies linked drugs like beta-blockers, methyldopa, and reserpine to depression, more recent evidence suggests these associations are weaker than previously thought. Some cardiovascular drugs may even have beneficial neuropsychiatric effects, such as clonidine for ADHD and propranolol for performance anxiety .
Adherence to Cardiovascular Medications: Challenges and Outcomes
Adherence to cardiovascular medications is a significant challenge, with about 50% of patients showing poor adherence. Non-adherence is linked to worse clinical and economic outcomes, including higher mortality in patients with coronary artery disease. Factors affecting adherence include disease characteristics, therapy complexity, healthcare system issues, patient beliefs, and social factors. Interventions to improve adherence should target these modifiable factors and focus on high-risk groups Kronish2013Leslie2018Chen2022.
Access to Cardiovascular Medications in Low- and Middle-Income Countries
Access to cardiovascular medications is limited in many low- and middle-income countries due to issues with availability, affordability, and quality. Strategies to improve access include efficient procurement of low-cost generics, development of fixed-dose combinations, and insurance schemes that reduce out-of-pocket costs. Monitoring and policy interventions are needed to address these barriers .
Long-Term Use and Polypharmacy
Long-term use of cardiovascular drugs is common, especially after events like myocardial infarction. However, there is limited evidence from clinical trials on the long-term benefits and risks, as most studies have short follow-up periods. Polypharmacy, particularly in older adults, increases the risk of adverse effects and drug interactions. There is also a lack of evidence on the effects of withdrawing these medications, underscoring the need for more research and better education for healthcare providers .
New and Emerging Cardiovascular Medications
Despite the availability of effective cardiovascular drugs, there is ongoing development of new medications with different mechanisms of action. These new drugs show promise in treating hypertension, heart failure, stroke, and type 2 diabetes, and may be used alone or in combination with existing therapies. The hope is that these new agents will further reduce the burden of cardiovascular disease .
Repurposing Cardiovascular Drugs
Approved cardiovascular drugs are being explored for new uses beyond their original indications. For example, drugs like aspirin, beta-blockers, ACE inhibitors, and statins are being studied for their potential anti-tumor effects and other conditions. While experimental studies are promising, clinical trials have not always confirmed these benefits, but ongoing research continues to explore new possibilities .
Conclusion
Cardiovascular medications are essential for managing heart disease but are also a leading cause of medication-related harm, especially in older adults. Adherence, access, and long-term safety remain significant challenges. Ongoing research into new drugs and repurposing existing ones offers hope for improved outcomes, but careful monitoring and patient-centered approaches are needed to maximize benefits and minimize risks Paradissis2021Mladěnka2018Chrysant2020+7 MORE.
Sources and full results
Most relevant research papers on this topic